Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Profound Medical ( (TSE:PRN) ) is now available.
Profound Medical Corp. announced a schedule change for its presentation at the 43rd Annual J.P. Morgan Healthcare Conference, now occurring at 9:00 a.m. PT on January 16, 2025. This update may enhance the company’s visibility among investors and stakeholders, potentially impacting its operations and industry positioning positively by showcasing its innovative medical devices and therapeutic technologies.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company focusing on the development and marketing of customizable, incision-free therapies for diseased tissue ablation. Its primary products include the TULSA-PRO® system for prostate disease treatment and Sonalleve® for uterine fibroids and palliative pain treatment of bone metastases. The company aims to expand its market presence in non-invasive medical procedures with regulatory approvals across multiple regions.
YTD Price Performance: -4.72%
Average Trading Volume: 9,964
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$327M
For an in-depth examination of PRN stock, go to TipRanks’ Stock Analysis page.
